F C Breedveld Selected Research

Necrosis

08/2008	Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis.
11/2005	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
10/2005	[Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept]
11/2004	Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
12/2003	Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

Articles by Research Topic

Disease

49	Rheumatoid Arthritis 06/2008 - 01/2000
5	Arthritis (Polyarthritis) 09/2008 - 03/2000
5	Necrosis 08/2008 - 12/2003
3	Systemic Scleroderma (Systemic Sclerosis) 08/2004 - 12/2000
3	Inflammation 01/2001 - 02/2000
2	Rheumatic Diseases (Rheumatism) 11/2005 - 11/2004
1	Knee Osteoarthritis 08/2008
1	Osteoarthritis 04/2005
1	Tuberculosis 04/2003
1	Skin Diseases 06/2001
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2000

Drug/Important Bio-Agent (IBA)

11	Methotrexate (Mexate)FDA LinkGeneric 07/2007 - 05/2000
7	infliximab (Remicade)FDA Link 07/2007 - 11/2000
6	AntibodiesIBA 05/2008 - 01/2000
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2005 - 11/2000
5	leflunomide (Arava)FDA LinkGeneric 09/2004 - 07/2000
3	Interleukin-1 (Interleukin 1)IBA 11/2005 - 02/2002
3	adalimumab (Humira)FDA Link 10/2005 - 12/2003
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2008 - 12/2006
2	Interleukin-10 (Interleukin 10)IBA 08/2008 - 07/2003
2	HLA-DRB1 antigen (HLA DRB1)IBA 05/2008 - 03/2006
2	cyclic citrullinated peptideIBA 12/2006 - 01/2000
2	TNFR-Fc fusion protein (etanercept)FDA Link 10/2005 - 09/2001
2	Granzymes (Granzyme)IBA 05/2004 - 01/2001
2	PeptidesIBA 03/2004 - 12/2000
2	Immunoglobulin G (IgG)IBA 02/2003 - 12/2002
2	AntigensIBA 02/2003 - 11/2001
2	Histocompatibility Antigens Class IIIBA 04/2002 - 02/2001
2	human CHI3L1 proteinIBA 12/2000 - 07/2000
1	cartilage matrix proteinIBA 06/2008
1	Rheumatoid FactorIBA 05/2008
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 08/2007
1	rituximab (Mabthera)FDA Link 02/2007
1	GTP Phosphohydrolases (GTPases)IBA 10/2006
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2006
1	MicronutrientsIBA 06/2004
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2004
1	AutoantibodiesIBA 03/2004
1	Antirheumatic Agents (DMARD)IBA 12/2003
1	CytokinesIBA 07/2003
1	Matrix MetalloproteinasesIBA 07/2003
1	Tranexamic Acid (AMCA)FDA Link 05/2003
1	Plasmin (Fibrinolysin)FDA Link 05/2003
1	Leucovorin (Folinic Acid)FDA LinkGeneric 07/2001
1	Interleukin-8 (Interleukin 8)IBA 01/2001
1	CitrullineIBA 01/2001
1	Proteoglycans (Proteoglycan)IBA 01/2001
1	Calcitriol (Calcijex)FDA LinkGeneric 12/2000
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 05/2000
1	Bacterial DNAIBA 03/2000
1	Metalloproteases (Metalloproteinases)IBA 02/2000
1	Interferon-betaIBA 02/2000
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2000
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 01/2000
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2000

Therapy/Procedure

3	Stem Cell Transplantation 08/2004 - 06/2001
2	Drug Therapy (Chemotherapy) 08/2005 - 04/2001
2	Hematopoietic Stem Cell Transplantation 08/2005 - 04/2001
1	Musculoskeletal Manipulations (Manipulative Therapy) 04/2005
1	Aftercare (After-Treatment) 01/2005